Tyrosine kinase inhibitors (TKIs) are widely used to treat patients with chronic myelogenous leukemia in the chronic phase (CML-CP), and outcomes of TKI treatment for patients with CML-CP have been excellent. Since multiple TKIs are currently available, second-line or third-line TKI therapy is considered for patients who are intolerant of or resistant to the previous TKI treatment. Therefore, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered only for patients with disease progression or for patients after treatment failure with multiple TKIs. To reflect the current clinical situation of patients with CML-CP, we tried to clarify whether prior TKI treatment affects the outcome of allo-HSCT. Data from 237 patients for whom the number of pretransplant TKIs varied from one to three were used for analysis. Before allo-HSCT, 153 patients were treated with one TKI, 49 patients were treated with two TKIs and 35 patients were treated with three TKIs. In addition to conventional risk factors, i.e., disease status at transplantation and patient's age, the use of three TKIs before transplantation was identified as a significant adverse factor for prognosis. Nonrelapse mortality rate was higher in patients treated with three TKIs than in patients treated with one or two TKIs. Our results suggest that allo-HSCT could be considered for young patients with CML-CP who manifest resistance to second-line TKI therapy and who have an appropriate donor.
| I N T R O D U C T I O N
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized by the presence of the Philadelphia chromosome (Ph), which results from a reciprocal translocation between chromosomes 9 and 22. As a result of formation of t(9;22)(q34;q11), a novel fusion gene, Bcr-abl, is formed, and the subsequent chimeric tyrosine kinase, BCR-ABL, is constitutively active and plays a critical role in the pathogenesis of CML. Until 2001, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the only curable treatment for CML and was thus proactively considered for transplant-eligible patients.
1,2 However, after the introduction of the tyrosine kinase inhibitor (TKI) imatinib, which blocks the ATP-binding site of BCR-ABL, allo-HSCT has lost its position as the primary treatment option for patients with newly diagnosed CML in the chronic phase (CP). The International Randomized
Study of Interferon versus STI571 (IRIS) for patients with newly diagnosed CML-CP showed that overall survival (OS) of patients treated with imatinib was 88% at 6 years. 3 In addition, the use of secondgeneration TKIs, dasatinib, nilotinib and bosutinib, has shown excellent results in patients with imatinib resistance or imatinib intolerance. [4] [5] [6] [7] [8] Furthermore, dasatinib and nilotinib showed higher efficacy than that of imatinib in treatment of patients with newly diagnosed CML-CP. 9, 10 Therefore, allo-HSCT is now considered for patients with disease progression or for patients after treatment failure with multiple TKIs. 11 Since there has been an interest in the possible impact of prior TKI treatment on the outcome of allo-HSCT, several retrospective studies on this issue were performed. However, the early studies were based on imatinib use before transplantation, and the numbers of patients in recent studies, including cases treated with second-generation TKIs, were small [12] [13] [14] [15] [16] [17] [18] . Many patients who undergo allo-HSCT have received second-line or third-line TKI therapy. Therefore, it should be determined whether prior TKI treatment affects the outcome of allo-HSCT.
To clarify this issue, we analyzed observational data provided by the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
| M E T H O D S

| Patients
Data for patients of at least 20 years of age who were diagnosed as having CML-CP between 2001 and 2012 and underwent allo-HSCT were collected through the Transplant Registry Unified Management Program (TRUMP). [19] [20] [21] Initially, data for 378 patients were collected. The criteria for inclusion of patients were (1) initially diagnosed as having CML-CP, (2) treated with at least one TKI, (3) available data for disease status at transplantation, (4) receiving first allo-HSCT and 5) available data for survival status. Data for 141 patients were excluded from the analysis since those patients did not fulfill the criteria for analysis (Supporting Information Figure S1 ). The data for the excluded patients are shown in Supporting Information. Other missing data were dealt with as missing data.
Data for 237 patients were used for analysis. The study was approved by the data management committees of the JSHCT as well as by the Ethical Committee of Hokkaido University Hospital.
| Pretransplant treatments and disease status at transplantation
All patients were diagnosed as having CML-CP and were primarily treated with a tyrosine kinase inhibitor. After the second-generation The intensity of the conditioning regimen, myeloablative or reduced intensity, was defined as previously described. 23 Briefly, a myeloablative conditioning regimen includes one of the following treatments:
total body irradiation 5 Gy in a single dose or 8 Gy fractionated or busulfan > 8 mg/kg orally or intravenous equivalent dose. Donor sources were related bone marrow (rBM), unrelated BM (uBM), related peripheral blood (rPB) and unrelated cord blood (CB). HLA matching was performed on the basis of low-resolution antigens of HLA-A and HLA-B and high-resolution molecular typing of HLA-DRB1 as previously described. 24 HLA antigen disparities were categorized as either GVH or HVG direction. Relapse was defined by the reappearance of not only blasts or the Philadelphia chromosome but also BCR-ABL fusion transcripts. Nonrelapse mortality (NRM) was defined as death during continuous remission.
| Statistical analysis
Group characteristics associated with patient-related variables were compared with the chi-squared test for categorical variables and analysis of variance (ANOVA) for continuous variables. OS was defined as the time between transplantation and death due to any cause.
Leukemia-free survival (LFS) was defined as the time interval from transplantation to the first event, either relapse or death, in patients who achieved complete remission. The probabilities of OS and LFS were calculated using the Kaplan-Meier method and were statistically analyzed by the log-rank test. Cumulative incidences of relapse and NRM were calculated by Gray's test. To examine the factors influencing OS ad LFS, the following variables were initially analyzed in univariate analysis: pretransplantation TKI use, graft source, donor-recipient gender combination, HLA disparities, disease status at transplantation, interval between diagnosis and transplantation, patient's age at transplantation, conditioning regimen and cytogenetic/molecular status at transplantation. Subsequently, a stepwise multivariate analysis was performed using the Cox regression model to identify potential prognostic factors for OS and LFS and by the Fine-Gray proportional hazard regression model for relapse incidence (RI) and NRM. P < .05 was used as a significance level.
| R E S U LTS
| Patient characteristics
The demographics of patients are shown in Table 1 Table   1 . Either the chi-squared test or ANOVA showed that duration from diagnosis to transplantation, conditioning regimen, disease status at transplantation and molecular response at transplantation were significantly different depending on the number of pretransplant TKIs used.
| Overall survival and leukemia-free survival
The median follow-up period after transplantation was 727 days (range, 13-4191 days). Two-year OS was 63.7% (95% CI, 57.0%-69.7%) and LFS was 57.0% (95% CI, 50.2%-63.1%) in all of the patients (Supporting Information Figure S2 ). According to the number of pre- Table S1 ). We also analyzed the prognostic impact of donor source, donor-recipient gender combination, HLA disparities, disease status at transplantation, duration from diagnosis to transplantation, patient's age at transplantation, intensity of the conditioning regimen, cytogenetic status of the Philadelphia chromosome at transplantation, and molecular status of bcr-abl transcript at transplantation.
In addition to TKI 5 3, donor source (cord blood), HLA disparities (both GVH and HVG directions), advanced disease stage at transplantation and patient's age (50 y.o.) had negative impacts on both OS and LFS, and no major cytogenetic response (no MCyR) had a negative impact on LFS (Supporting Information Table S1 and Figure S3 ). These factors were subjected to a stepwise multivariate analysis using the Cox regression model. As shown in Table S2 and Figure   S4 ). These factors were subjected to a stepwise multivariate analysis using the Fine-Gray proportional hazard regression model. As shown in Table 3 , advanced disease stage at transplantation was significantly associated with higher RI, and TKI 5 3 remained a significant adverse factor associated with higher NRM rate. Moreover, male recipient/ female donor combination and patient's age at transplantation (50 y.
o.) were identified as risk factors for NRM. Conversely, CB as a graft source, HLA disparities for GVH direction, pretransplant duration (3 years), intensity of conditioning regimen and cytogenetic status at transplantation were not significant factors after multivariate analysis, since these factors were tightly associated with significant adverse risk factors identified by multivariate analysis (Supporting Information).
| DISCUSSION
After TKIs became available for treatment of CML, the effect of pretransplant TKI use on the outcome of allo-HSCT was analyzed. Previous studies with a large number of patients showed that pretransplant imatinib use has no negative effect on the outcome of all-HSCT for CML. [12] [13] [14] [15] There have also been a few studies on second-generation TKI use before allo-HSCT. Although the results of those studies suggested that second-generation TKI use before allo-HSCT did not increase transplant-related toxicity, the number of patients was small and cases diagnosed not only as chronic phase but also as accelerated phase or blastic crisis were included in those studies. [16] [17] [18] Since treatment of CML-CP with a second-generation TKI has shown good therapeutic responses in imatinib-intolerant, imatinibresistant and newly diagnosed patients, allo-HSCT is now considered only for patients for whom treatment with at least 2 TKIs failed and for patients who progressed to an advanced phase. To reflect the current clinical situation of patients with CML-CP, our study was based on patients who were primarily treated with a TKI and underwent allo- From our analysis, TKI 5 3 was identified as an adverse risk factor for both OS and LFS, and the reason for patients with TKI 5 3 having a low survival rate was a higher rate of NRM. Moreover, HLA disparities for GVH direction, advanced age and advanced disease status at transplantation were associated with low rate of both OS and LFS. As expected, lower survival rates were ascribed to increased NRM rate in patients of advanced age (50 y.o.) and higher RI in patients with advanced disease status at transplantation. HLA disparity for GVH direction was a significant factor for both OS and LFS after multivariate analysis; however, it was significantly associated with RI only in univariate analysis. Conversely, male recipient/female donor combination was a significant risk factor for NRM by multivariate analysis, though it was not a significant adverse factor for OS or LFS. Therefore, HLA disparities for GVH direction and male recipient/female donor combination are potential clinical factors that affect patient prognosis.
Intriguingly, the results of our study showed that patients who received three TKIs (imatinib, nilotinib and dasatinib) before allo-HSCT had a lower survival rate than that of patients treated with one or two TKIs. The reason for patients with TKI 5 3 having inferior survival was increased NRM. Conversely, OS and LFS were similar in patients with TKI 5 1 and patients with TKI 5 2. It is difficult to determine the mechanism underlying the increased NRM in patients with TKI 5 3. Each TKI has multiple off-targets, which may have some effects on the immune system or vascular endothelial cells. Although treatment with three TKIs before allo-HSCT was shown to be a poor prognostic factor in our analysis, it should be pointed that most of the patients, 235 out of 237 patients, were primarily treated with imatinib. Because most of the analyzed patients were diagnosed before 2007, only available TKI was imatinib at the time of diagnosis.
In the current situation in CML treatment, a second-generation TKI is frequently chosen for both first-line and second-line treatment. Therefore, analysis for patients who are treated with TKIs other than imatinib and undergo all-HSCT is still required.
In addition to TKI 5 3, HLA disparities for GVH direction, advanced disease stage at transplantation and advanced age were identified as To determine the indication and timing of allo-HSCT for patients with CML, we need to evaluate the risks and benefits of the treatment.
After treatment failure with imatinib, a second-generation TKI is a choice of therapy. However, based on previous reports, long-term survival of patients who received second-line and third-line TKI treatment is not so good. It was reported that two-year OS and PFS rates in imatinib-resistant/intolerant patients were 91% and 80% with second-line dasatinib treatment, 87% and 64% with second-line nilotinib treatment and 92% and 79% with second-line bosutinib treatment, respectively. 8, 30, 31 Moreover, previous studies suggested that disease progression frequently occurs during third-line TKI treatment.
32,33
The long-term outcomes of patients with newly diagnosed CML, who were eligible for allo-HSCT and were randomized by availability of a matched family donor between allo-HSCT and best available drug treatment, have recently been reported. In that study, patients with an available related donor and low adapted EBMT score had significantly higher survival probability than did patients who received treated drug treatment. 34 Our results indicated that TKI 5 3 is a significant factor for survival after allo-HSCT besides disease progression and patient's age. Allo-HSCT could be considered for young patients with CML
showing resistance to second-line TKI therapy who did not have disease progression and who have an appropriate donor. 
